NCCS Develops AI Tool to Predict Liver Cancer Recurrence After Surgery
oncodaily - National Cancer Centre Singapore (NCCS) shared on LinkedIn: “Can we now predict who’s at greatest risk for liver cancer recurrence? Congratulations to NCCS’ Professor Pierce Chow, Associate Professor Wai Leong Tam, Mr. Karthik Sekar, […]
AI Summary: A newly developed AI model predicts risk of liver cancer recurrence following surgical resection, integrating imaging and clinical variables to stratify patients more accurately. Early validation suggests the tool could personalize surveillance intensity and adjuvant therapy decisions, reducing unnecessary exams for low‑risk patients while focusing resources where recurrence risk is highest.
International project delivers hundreds of next-generation models for cancer research
medicalxpress - Ten years and thousands of patient samples later, the National Cancer Institute (NCI) has published its results from the Human Cancer Model Initiative (HCMI) on the development of 665 organoid models of 25 types of cancer that are now available to scienti…
AI Summary: An international consortium released hundreds of patient‑derived tumor models, including a public HCMI set of 665 organoids, creating a living biobank for drug discovery. Labs worldwide now gain access to diverse, next‑generation models to test therapies and probe cancer vulnerabilities — a major boost for preclinical translational work.
- Experts react: three Nature papers and model summaries (3)
- HCMI release: 665 organoids unveiled in Nature (4)
- Organoids power maps and predictors of therapy resistance (4)
Experts react: three Nature papers and model summaries
HCMI release: 665 organoids unveiled in Nature
Organoids power maps and predictors of therapy resistance
Recovery for Replimune: Accelerated Approval for Cancer Drug Twice Spurned by FDA
Frank Vinluan / medcitynews - Replimune went from an FDA rejection to a resubmission, a positive advisory committee vote, and finally an accelerated regulatory approval for advanced melanoma — all in less than four months. The FDA nod for Replimune’s oncolytic viral therapy, Tudriqev,…
AI Summary: After two previous turns in the penalty box, the FDA granted accelerated approval to Replimune’s oncolytic immunotherapy Tudriqev (RP1) in combination with nivolumab for advanced melanoma. The decision follows a favorable advisory committee outcome and positions a once-spurned viral-based therapy back into the clinic as a new option for patients with limited choices.
- Clinical community reaction and rollout: experts and training (4)
- Regulatory comeback: FDA approves Tudriqev after two rejections (4)
- Replimune announcements and company leadership reactions (3)
- All Other Stories
Clinical community reaction and rollout: experts and training
Regulatory comeback: FDA approves Tudriqev after two rejections
Replimune announcements and company leadership reactions
All Other Stories
NICE referral criteria miss up to 95% of women under 50 who go on to develop breast cancer within 10 years
medicalxpress - The National Institute for Health and Care Excellence (NICE) criteria used to decide who should be referred by GPs for further breast cancer risk assessment and specialist care miss up to 95% of women under 50 who will go on to develop the disease in the …
AI Summary: A recent analysis finds current NICE referral and screening criteria fail to flag the vast majority of women under 50 who later develop breast cancer, prompting criticism of one‑size‑fits‑all approaches. Researchers propose a new risk‑stratified method that could identify many more younger at‑risk women, pushing for policy updates to catch cancers earlier.
William Dale: Meeting Ethiopian National Leaders in Oncology and Palliative Care in Addis Ababa
oncodaily - William Dale, Professor and Vice Chair for Academic Affairs and Director, Center for Cancer and Aging at City of Hope, shared on LinkedIn: ”I have had the most remarkable week […]
AI Summary: William Dale traveled to Ethiopia to meet national health leaders and frontline clinicians, spotlighting geriatric oncology, palliative care and patient-centered cancer services. The visit included hospital engagements, training sessions and advocacy for system-wide improvements to strengthen cancer care access and workforce capacity across Ethiopian institutions.
This amino acid may help the body fight tumors and viral infections
medicalxpress - The amino acid arginine helps keep the human body humming, most notably by synthesizing proteins that carry out a range of cellular processes. It's produced by our bodies and found in common high-protein foods. Low levels of arginine are associated with a…
AI Summary: New research implicates the amino acid histidine in modulating immune and tumor biology, suggesting it may enhance anti-tumor responses and antiviral defenses in preclinical studies. Scientists report mechanistic insights that could inform future therapeutic strategies, although translation to patients will require careful testing—because promising mouse data still need to pass the human audit.
ASCO Names 34 Oncology Leaders as 2027 FASCO Fellows
oncodaily - The American Society of Clinical Oncology (ASCO) has recognized 34 oncology professionals with the 2027 Fellow of the American Society of Clinical Oncology designation, honoring their sustained service, engagement, and […]
AI Summary: ASCO announced its 2027 FASCO fellows, recognizing 34 oncology leaders for sustained contributions in clinical care, research and education. The class includes clinicians and investigators receiving individual congratulations for their impact on cancer practice and policy—official recognition that translates into prestige, networking opportunities, and the occasional humble‑brag.
FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma
esmo - Evidence for efficacy is based on the results from the LITESPARK-022 study
AI Summary: Regulators have cleared the combination of belzutifan and pembrolizumab as adjuvant therapy for renal cell carcinoma at high risk of recurrence after nephrectomy. Clinical data showed improved disease‑free survival versus control, offering a new post‑surgery option intended to delay recurrence in patients with residual recurrence risk.
New treatment approach improves survival, reduces recurrence risk in muscle-invasive bladder cancer
medicalxpress - Researchers have found that a combination of enfortumab vedotin and pembrolizumab helps patients with muscle-invasive bladder cancer live longer while reducing the risk that their cancer will return after surgery, according to an international phase 3 cli…
AI Summary: Practice‑changing data and a network meta‑analysis have clarified perioperative strategies for muscle‑invasive bladder cancer, showing that certain neoadjuvant and adjuvant approaches improve survival and reduce recurrence. Recent trial results and comparative evidence are prompting shifts in treatment sequencing for cisplatin‑eligible patients, moving the needle on standards of care.
- Biomarkers and AI Predict Immunotherapy Benefit and Toxicity (4)
- EV‑Pembrolizumab: New Perioperative Standard for Cisplatin‑Eligible MIBC (4)
- Neoadjuvant Combinations and Bladder Preservation Trials (4)
- Network Meta-Analysis Clarifies Optimal Perioperative Strategies (3)
- All Other Stories
Biomarkers and AI Predict Immunotherapy Benefit and Toxicity
EV‑Pembrolizumab: New Perioperative Standard for Cisplatin‑Eligible MIBC
Neoadjuvant Combinations and Bladder Preservation Trials
Network Meta-Analysis Clarifies Optimal Perioperative Strategies
All Other Stories
It has begun: Foxconn amassing army of workers for iPhone 18 Pro assembly
appleinsider - Months ahead of the fall launches, and historically right on time, Apple supply chain partner Foxconn has started to hire a small army of assemblers to build the iPhone 18 Pro.Workers at a Foxconn facility - Image source: FoxconnEach summer, the Apple sup…
AI Summary: Agenus has suspended the BATTMAN clinical trial and announced a follow‑on program called ROBBIN after strategic reassessment, a move that has raised questions about transparency and participant communication. The abrupt pivot highlights tensions between rapid corporate decision‑making and the need to maintain patient trust in oncology research.
The AACR Rare Cancers Initiative: Uniting Researchers, Undoing Barriers, and Unleashing Progress
Steve Schneible / aacr - At the recent AACR Special Conference on Breaking Barriers in the Fight Against Rare Cancers, AACR Immediate Past President Lillian L. Siu, MD, FAACR, announced the AACR Rare Cancers Initiative. Learn more about how this new Initiative will marshal global…
AI Summary: The AACR has unveiled a Rare Cancers Initiative to coordinate researchers, streamline data sharing, and speed therapeutic development for uncommon tumor types. By pooling expertise, funding and networks, the program seeks to overcome the chronic scarcity of trials and resources that leave rare‑cancer patients waiting for attention that’s been hard to come by.
Gregory Lesinski: Winship Team Publishes Novel CAR/VIPRa T-Cell Therapy in Science
oncodaily - Gregory Lesinski, Associate Director of Basic Research at Winship Cancer Institute of Emory University, shared on LinkedIn by Sarwish Rafiq, Assistant Professor at the Emory University School of Medicine and […]
AI Summary: Researchers published a novel CAR T‑cell approach exploiting the VIP–VIPR pathway that reprograms cells for superior antitumor activity in preclinical models. The Winship team’s paper reports enhanced tumor killing and durability in laboratory studies, flagging a promising route to improve CAR T efficacy in solid tumors — still very early, but intriguing.
FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial
Adam D. Cohen / nature - Nature Medicine, Published online: 22 July 2026; doi:10.1038/s41591-026-04522-3In a phase 1 trial, the maximum tolerated dose for an FcRH5-containing bispecific T cell engager was not reached, and there was an encouraging response rate in patients with re…
AI Summary: A phase 1 study of the FcRH5×CD3 bispecific antibody cevostamab reported manageable safety and early signals of activity in relapsed or refractory multiple myeloma. Investigators outlined dosing, adverse events and preliminary responses, setting the stage for larger studies and combination trials as patients and advocates watch for broader access to T‑cell‑engaging therapies.
$10B M&A Deal Pays Off With GSK’s First Lung Cancer Drug Approval
Frank Vinluan / medcitynews - GSK drug Jideytro received FDA approval for treating advanced cases of non-small cell lung cancer driven by ROS1 alterations. This molecule came from Nuvalent, which GSK recently acquired for $10.6 billion. The post $10B M&A Deal Pays Off With GSK’s First…
AI Summary: GSK has won FDA approval for its first lung cancer drug, a gene-targeting therapy that validates the company’s heavy investment and recent M&A strategy. The approval follows pivotal trial evidence of clinical benefit and positions GSK competitively in thoracic oncology, offering a new therapeutic choice for patients with the relevant molecular profile.
Tempus buys out cancer genomics partner Personalis in $1.5 billion deal
fiercehealthcare - Tempus is boosting its cancer offerings with a deal to buy out Personalis three years after the pair first teamed up in oncology.
AI Summary: Tempus is acquiring cancer-genomics company Personalis for roughly $1.5 billion to expand its testing and genomic-service footprint, betting bigger on integrated sequencing and AI-driven oncology diagnostics. The move accelerates Tempus’s push to scale tumor profiling and clinical assays nationwide — and yes, expect louder claims about “transforming cancer care.”
How we are engineering bacteria to eat cancer
medicalxpress - Modern medicine has made significant advances in cancer treatments over the decades. But all cancer therapies still face one critical challenge: how to target cancers without damaging healthy cells.
AI Summary: Researchers engineered bacteria that selectively attack and consume tumor tissue in preclinical models, demonstrating promising tumor control and a novel mechanism to deliver anti‑cancer effects. Significant questions remain about safety, immune responses and delivery in humans, so while the “bacteria that eat cancer” headline is delightful, translation to patients will require cautious, rigorous steps.
Researchers identify immune cell that builds cancer-fighting hubs inside tumors
medicalxpress - Researchers at the Icahn School of Medicine at Mount Sinai have identified the immune cell that acts as the architect and coordinator of powerful immune hubs that form inside tumors and plays a key role in antitumor immunity. This discovery could lead to …
AI Summary: Researchers discovered a subset of dendritic cells that orchestrate formation and maintenance of tertiary lymphoid structures—local immune “hubs”—inside tumours. These niches concentrate and sustain anti-tumour T cells, explaining how some cancers spontaneously marshal immune responses and opening avenues to boost immunotherapy by enhancing or mimicking this dendritic cell-driven architecture.
- Discovery: dendritic cells build tumour immune hubs (3)
- Molecular and systemic regulators of tumour immune hubs (3)
- Therapeutic strategies: boosting T cells and DC vaccines (3)
Discovery: dendritic cells build tumour immune hubs
Molecular and systemic regulators of tumour immune hubs
Therapeutic strategies: boosting T cells and DC vaccines
Stephen Liu: AstraZeneca Reaches Deal with Dizal to Bring Sunvozertinib to the US!
oncodaily - Stephen Liu, Director of Thoracic Oncology, Chief of the Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared on X: “FINALLY! AstraZeneca reaches deal with Dizal […]
AI Summary: AstraZeneca reached a deal to make sunvozertinib available in the U.S., accelerating global access for patients with EGFR exon 20 insertion–positive non–small cell lung cancer. The move follows encouraging WU-KONG1B data and signals commercial partnerships are finally translating niche trial gains into real-world treatment options for a stubbornly underserved subgroup.
- AstraZeneca-Dizal deal opens US access to sunvozertinib (3)
- Testing, treatment gaps and rising rare-NSCLC approvals (3)
- WU-KONG1B confirms sunvozertinib activity in EGFR Exon20 (3)
AstraZeneca-Dizal deal opens US access to sunvozertinib
Testing, treatment gaps and rising rare-NSCLC approvals
WU-KONG1B confirms sunvozertinib activity in EGFR Exon20
The RAS Inhibitor Daraxonrasib is Showing Encouraging New Results – Dana-Farber
oncodaily - Dana-Farber Cancer Institute shared a post on LinkedIn: “For years, RAS was considered one of the toughest targets in cancer research. In pancreatic cancer, that challenge is especially urgent. New […]
AI Summary: A targeted RAS inhibitor, daraxonrasib, produced promising clinical activity in patients with NRAS-mutant melanoma, demonstrating tumor responses and a tolerable safety profile in early studies. The data suggest a viable therapeutic avenue for a historically hard-to-treat subset and justify larger trials to confirm benefit — because apparently NRAS wasn’t going to cure itself.
Stopping myeloma maintenance after two years shows no survival loss in trial
medicalxpress - For patients with newly diagnosed multiple myeloma not undergoing an autologous stem cell transplant, indefinite lenalidomide maintenance has long been standard care despite limited evidence to guide the optimal duration of treatment. A randomized phase 3…
AI Summary: Long‑term follow‑up from a randomized multiple myeloma maintenance study indicates that stopping lenalidomide after two years yields similar overall survival to continuing indefinitely. The data support a limited‑duration maintenance strategy that may spare patients toxicity and costs without sacrificing outcomes — revolutionary for weary patients and budget‑conscious oncologists alike.
- Clinicians and advocates react: praise and guidance after ENDURANCE results (6)
- ENDURANCE trial: Two-year lenalidomide equals continuous therapy (3)